Oncologists' agreement on adjuvant therapy recommendations and the need of 21-gene recurrence score assay in HR+/HER2-early breast cancer

被引：0
|
作者：
Castro-Henriques, M. [1 ]
Casadevall Aguilar, D. [2 ]
Monzonis, X. [2 ]
Martinez-Garcia, M. [2 ]
Martos, T. [2 ]
Corbera, A. [2 ]
Trias Bes, I. Tusquets [2 ]
Albanell, J. [2 ]
Servitja, S. [2 ]
机构：
[1] HM Hosp, Hosp HM Delfos, Ctr Integral Oncol Clara Campal HM CIOCC, Dept Med Oncol, Barcelona, Spain
[2] Hosp del Mar, Med Oncol Dept, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
186P
引用
收藏
页码：S317 / S317
页数：1
相关论文
共 50 条
  • [41] Survival outcome of adjuvant chemotherapy and high 21-gene recurrence score in early-stage breast cancer
    Ma, Sung Jun
    Oladeru, Oluwadamilola T.
    Farrugia, Mark
    Mikucki, Maryann
    Iovoli, Austin
    Shekher, Rohil
    Sood, Amit
    Singh, Anurag K.
    BREAST JOURNAL, 2021, 27 (01): : 27 - 34
  • [42] PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer
    Mayer, E.
    DeMichele, A.
    Dubsky, P.
    Barry, W.
    Metzger, O.
    Symmans, W. F.
    Burstein, H.
    Miller, K.
    Wolff, A.
    Rastogi, P.
    Loibl, S.
    von Minckwitz, G.
    Goulioti, T.
    Zardavas, D.
    Fesl, C.
    Koehler, M.
    Bartlett, C. Huang
    Chen, L.
    Piccart, M.
    Winer, E.
    Gnant, M.
    CANCER RESEARCH, 2016, 76
  • [43] Recurrence Score of 21-Gene Assay Is Correlated with a Panel of Immunopathological Factors of Breast Cancer
    Subik, K.
    Delaney, A.
    Wang, J.
    Wang, X.
    Schiffhauer, L. M.
    Shayne, M.
    Huston, A.
    Skinner, K.
    Hicks, D. G.
    Tang, P.
    MODERN PATHOLOGY, 2010, 23 : 74A - 74A
  • [44] The performance of the 21-gene assay standard cutpoints of 18 and 31 in HR+, HER2-invasive breast cancer (BC), while waiting for TAILORx mid-range recurrence score results.
    Miller, Dave P.
    Petkov, Valentina I.
    Shak, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] How 21-gene recurrence score assay is being used to individualize adjuvant chemotherapy recommendations in ER+/HER2-node positive breast cancer -A national cancer data base study
    Peethambaram, P. P.
    Hoskin, T. L.
    Heins, C. N.
    Habermann, E. B.
    Boughey, J. C.
    CANCER RESEARCH, 2017, 77
  • [46] YAP1 Expression in HR+HER2-Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
    Park, Inho
    Lee, Yangkyu
    Kim, Jee Hung
    Bae, Soong June
    Ahn, Sung Gwe
    Jeong, Joon
    Cha, Yoon Jin
    CANCERS, 2023, 15 (20)
  • [47] The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?
    Jerzak, Katarzyna J.
    Pritchard, Kathleen I.
    EUROPEAN JOURNAL OF CANCER, 2016, 68 : 173 - 175
  • [48] The 21-gene recurrence score and effects of adjuvant radiotherapy after breast conserving surgery in early-stage breast cancer
    Dong, Yong
    Zhang, Wen-Wen
    Wang, Jun
    Sun, Jia-Yuan
    He, Zhen-Yu
    Wu, San-Gang
    FUTURE ONCOLOGY, 2019, 15 (14) : 1629 - 1639
  • [49] Health-Related Quality of Life Among Patients With HR+/HER2-Early Breast Cancer
    Criscitiello, Carmen
    Spurden, Dean
    Piercy, James
    Rider, Alex
    Williams, Rhys
    Mitra, Debanjali
    Wild, Rosie
    Corsaro, Massimo
    Kurosky, Samantha K.
    Law, Ernest H.
    CLINICAL THERAPEUTICS, 2021, 43 (07) : 1228 - +
  • [50] 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer
    Chen, Xiang-Hong
    Zhang, Wen-Wen
    Wang, Jun
    Sun, Jia-Yuan
    Li, Feng-Yan
    He, Zhen-Yu
    Wu, San-Gang
    BIOMARKERS IN MEDICINE, 2019, 13 (02) : 83 - 93
12345